Pediatric Langerhans cell histiocytosis patients Langerhans cell histiocytosis Time of diagnosis Survival Risk organs Chemotherapy
Conditions
Interventions
Pediatric Langerhans cell histiocytosis patients who were treated at Phramongkutklao Hospital
Treatment
Langerhans cell histiocytosis patients
Sponsors
Office of Research and Development, Phramongkutklao Hospital and College of Medicine
Eligibility
Sex/Gender
All
Age
No minimum to 21 Years
Inclusion criteria
Inclusion criteria: Newly diagnosed Langerhans cell histiocytosis between January 1, 1997 and December 31, 2016 who were treated at Phramongkutklao Hospital
Exclusion criteria
Exclusion criteria: Langerhans cell histiocytosis patients who had no tissue histology to confirm diagnosis and not treated primarily at Phramongkutklao Hospital.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival and relapse rate of Langerhans cell histiocytosis patients 1 year Descriptive statistics and chi-squared test with p-value < 0.05 | — |
Secondary
| Measure | Time frame |
|---|---|
| Chemotherapy regimens affecting outcomes of Langerhans cell histiocytosis patient 1 year Descriptive statistics and chi-squared test with p-value < 0.05 ,Clinical characteristics of Langerhans cell histiocytosis patients 1 year Descriptive statistics and chi-squared test with p-value < 0.05 ,Prevalence of pediatric Langerhans cell histiocytosis 1 year Descriptive statistics and chi-squared test with p-value < 0.05 | — |
Countries
Thailand
Contacts
Public ContactChalinee Monsereenusorn
Phramongkutklao Hospital and College of Medicine
Outcome results
None listed